Vir Biotech Insider Sale: 22,000 Shares Sold Under 10b5-1 Plan

Rhea-AI Filing Summary

Vicki L. Sato, a director of Vir Biotechnology, Inc. (VIR), sold 22,000 shares on 09/02/2025 under a Rule 10b5-1 trading plan adopted March 27, 2025. The reported weighted-average sale price was $4.9914, with individual sale prices ranging from $4.88 to $5.07. After the reported sales, the filing shows 1,254,391 shares beneficially owned by the reporting person. The Form 4 was signed by an attorney-in-fact on 09/03/2025 and discloses that full breakdowns of shares sold at each price are available upon request.

Positive

• Sale executed under a documented Rule 10b5-1 trading plan, which enhances compliance transparency
• Reporting person retains a substantial holding after the sale (1,254,391 shares)

Negative

• Disposition of 22,000 shares reduces the reporting persons direct stake
• Sale executed at market prices (weighted avg $4.9914; range $4.88 $5.07), which may modestly increase share supply near those price levels

Insights

Corporate Governance Expert

TL;DR: Insider sale executed under a documented 10b5-1 plan reduces appearance of opportunistic trading.

The filing shows a routine disposition by a company director using a pre-established Rule 10b5-1 plan, which is a commonly used compliance mechanism to mitigate questions about insider timing. The sale size (22,000 shares) should be evaluated relative to the director's remaining position of 1,254,391 shares; here the sale represents a small fraction of total holdings, suggesting no change in control or material shift in alignment with shareholders. The disclosure of the price range and undertaking to provide per-price breakdowns is appropriate and improves transparency.

Securities Analyst

TL;DR: Transaction is a disclosed insider liquidation under plan terms, with limited immediate market impact.

The weighted-average price of $4.9914 and the disclosed price range ($4.88–$5.07) indicate executions over multiple trades rather than a single block trade. The remaining beneficial ownership of 1.25 million shares retains substantial insider exposure. There is no indication of derivative transactions or amendments to prior filings in this Form 4. For investors, the material facts are the use of a 10b5-1 plan and the modest scale of the sale versus total holdings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SATO VICKI L

(Last) (First) (Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO CA 94158

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		S(1)		22,000	D	$4.9914(2)	1,254,391	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.88 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Remarks:

	/s/ Vanina de Verneuil, Attorney-In-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Vicki L. Sato report on Form 4 for VIR?

The report discloses that Vicki L. Sato sold 22,000 shares of Vir Biotechnology on 09/02/2025 pursuant to a Rule 10b5-1 plan.

At what price were the VIR shares sold in the Form 4?

The filing reports a weighted-average sale price of $4.9914 and states individual sale prices ranged from $4.88 to $5.07.

How many VIR shares does the reporting person own after the sale?

After the reported transactions the reporting person beneficially owned 1,254,391 shares.

Was the sale part of a trading plan for VIR insiders?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on March 27, 2025.

Who signed the Form 4 filing for the reporting person?

The Form 4 was signed by Vanina de Verneuil, Attorney-In-Fact on 09/03/2025.